Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Work In Process (2016 - 2025)

Ocular Therapeutix has reported Work In Process over the past 11 years, most recently at $1.7 million for Q4 2025.

  • Quarterly results put Work In Process at $1.7 million for Q4 2025, up 15.58% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (up 15.58% YoY), and the annual figure for FY2025 was $1.7 million, up 15.58%.
  • Work In Process for Q4 2025 was $1.7 million at Ocular Therapeutix, up from $1.4 million in the prior quarter.
  • Over the last five years, Work In Process for OCUL hit a ceiling of $1.8 million in Q1 2025 and a floor of $402000.0 in Q1 2021.
  • Median Work In Process over the past 5 years was $907000.0 (2022), compared with a mean of $995800.0.
  • Biggest five-year swings in Work In Process: soared 650.67% in 2021 and later dropped 2.93% in 2025.
  • Ocular Therapeutix's Work In Process stood at $605000.0 in 2021, then skyrocketed by 48.6% to $899000.0 in 2022, then grew by 12.57% to $1.0 million in 2023, then soared by 47.13% to $1.5 million in 2024, then rose by 15.58% to $1.7 million in 2025.
  • The last three reported values for Work In Process were $1.7 million (Q4 2025), $1.4 million (Q3 2025), and $1.7 million (Q2 2025) per Business Quant data.